Division of Infectious Diseases, Department of Medicine, University of Utah, Salt Lake City, Utah, USA.
Division of Clinical Microbiology, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S314-S320. doi: 10.1093/cid/ciad541.
The advancement of infectious disease diagnostics, along with studies devoted to infections caused by gram-negative and gram-positive bacteria, is a top scientific priority of the Antibacterial Resistance Leadership Group (ARLG). Diagnostic tests for infectious diseases are rapidly evolving and improving. However, the availability of rapid tests designed to determine antibacterial resistance or susceptibility directly in clinical specimens remains limited, especially for gram-negative organisms. Additionally, the clinical impact of many new tests, including an understanding of how best to use them to inform optimal antibiotic prescribing, remains to be defined. This review summarizes the recent work of the ARLG toward addressing these unmet needs in the diagnostics field and describes future directions for clinical research aimed at curbing the threat of antibiotic-resistant bacterial infections.
传染病诊断学的进步,以及针对革兰氏阴性菌和革兰氏阳性菌感染的研究,是抗菌药物耐药性领导组(ARLG)的首要科学重点。传染病诊断检测技术正在迅速发展和改进。然而,能够直接在临床标本中确定抗菌药物耐药性或敏感性的快速检测方法仍然有限,尤其是针对革兰氏阴性菌。此外,许多新检测方法的临床影响,包括了解如何最好地使用这些方法来指导最佳抗生素处方,仍有待确定。这篇综述总结了 ARLG 在解决诊断领域这些未满足需求方面的最新工作,并描述了旨在遏制抗生素耐药性细菌感染威胁的临床研究的未来方向。